Fuda Cancer Hospital
Small intestine cancer treatment cost in China typically runs from $14,500 to $26,500 for primary surgical interventions. Expenses depend on the disease stage, specific therapy protocols, and the hospital tier. International patients can expect 60% to 80% savings compared to the United States. Guangzhou and Xiamen are leading cities providing specialized oncological care for this condition.
Typical Small Intestine Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients find the best value at specialized centers like Fuda Cancer Hospital. They offer over 10 minimally invasive options, including NanoKnife and cryosurgery. This is ideal for those seeking alternatives to traditional chemotherapy. For cases requiring complex radiation, Xiamen Humanity Hospital provides advanced technologies like VMAT and SBRT. These JCI-accredited facilities offer high-tech care at competitive international rates.
| China | Turkey | Austria | |
| Small intestine resection | from $14,500 | from $3,823 | from $25,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Radiation therapy for bowel cancer | from $10,500 | from $5,800 | from $6,951 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $22,500 | from $6,500 | from $40,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Primary treatment for small intestine cancer in China centers on surgical resection and advanced minimally invasive therapies. High-volume oncology centers prioritize R0 resection, often using laparoscopic or robotic techniques for faster recovery. Specialized facilities also utilize local ablation and hyperthermic intraperitoneal chemotherapy to manage advanced cases.
Bookimed Expert Insight: Patient data highlights a significant trend at specialized facilities like Fuda Cancer Hospital in Guangzhou. While standard protocols follow surgery with chemotherapy, these centers successfully substitute systemic drugs with minimally invasive ablative technologies. This approach is particularly effective for stage 3 or 4 patients who cannot tolerate the toxicity of traditional chemo regimens.
Patient Consensus: Patients emphasize the importance of choosing tertiary cancer centers with high surgeon experience in rare gastrointestinal tumors. They note that securing a second pathology review and detailed molecular testing is vital for determining if immunotherapy is an option.
Tumor location within the small intestine directly dictates the surgical approach and complexity. Upper tumors in the duodenum often require intricate multi-organ procedures like the Whipple. Conversely, tumors in the jejunum or ileum typically allow for standard bowel resections and direct reattachment.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital in Guangzhou utilize advanced techniques like NanoKnife for tumors in anatomically complex areas. Our data shows these facilities often manage over 30,000 international patients. This specialized experience is critical for duodenal cases where traditional surgery is high-risk.
Patient Consensus: Patients note that tumors located higher in the intestine cause blockage symptoms much earlier. They emphasize asking surgeons exactly how many centimeters of the bowel will be removed.
Top Chinese oncology centers in Guangzhou and Beijing specialize in treating advanced or unresectable small intestine cancer. These JCI-accredited facilities utilize cryosurgery and NanoKnife to target inoperable tumors. Specialized multidisciplinary teams integrate hyperthermic intraperitoneal chemotherapy (HIPEC) with vascular intervention for complex cases.
Bookimed Expert Insight: Data shows Fuda Cancer Hospital has treated over 30,000 patients from 100 countries. Their focus shifts from traditional surgery to microwave hyperthermia and cryosurgery for late-stage cases. This specific focus on minimally invasive local destruction is a key differentiator for unresectable tumors.
Patient Consensus: Patients note it is vital to bring original pathology slides and imaging discs for re-staging. Seeking second opinions at high-volume academic hospitals helps confirm if a tumor is truly unresectable.
The 3C+P model for gastrointestinal cancers in China is a comprehensive multidisciplinary management strategy. It integrates traditional chemotherapy, traditional Chinese medicine, and supportive care with precision medicine. This protocol aims to reduce therapy side effects while targeting specific molecular markers in advanced tumors.
Bookimed Expert Insight: While various 3C+P versions exist, JCI-accredited facilities like Fuda Cancer Hospital emphasize technological integration. They combine traditional pillars with advanced minimally invasive therapies like Cryosurgery or NanoKnife. This high-volume expertise is critical for rare conditions like small intestine cancer. Centers like Xiamen Humanity Hospital further refine the model. They utilize precision radiotherapy techniques including IMRT and VMAT for abdominal malignancies. Patients should confirm which specific technologies are bundled into a center's 3C+P protocol before booking.
Patient Consensus: Patients note that small intestine cancer requires specific surgical expertise rather than just a general protocol label. Many emphasize bringing physical pathology slides and imaging CDs to ensure the multidisciplinary team has accurate data for planning.
Bookimed Expert Insight: While Chinese hospitals serve thousands of international patients, integration levels vary by facility. Elite centers like Fuda Cancer Hospital combine minimal interventions like cryosurgery with TCM consultation. This hybrid approach often attracts patients seeking alternatives when standard systemic chemotherapy feels too taxing.
Patient Consensus: Patients note that TCM is vital for emotional comfort and improving appetite during recovery. Most emphasize using herbs only as an add-on to surgery to avoid dangerous delays.